- Home
- RLTY vs SOPH Comparison
RLTY vs SOPH Comparison
Compare RLTY & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- SOPH
- Stock Information
- Founded
- RLTY 2022
- SOPH 2011
- Country
- RLTY United States
- SOPH Switzerland
- Employees
- RLTY N/A
- SOPH N/A
- Industry
- RLTY Investment Managers
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RLTY Finance
- SOPH Health Care
- Exchange
- RLTY Nasdaq
- SOPH Nasdaq
- Market Cap
- RLTY 255.0M
- SOPH 214.9M
- IPO Year
- RLTY N/A
- SOPH 2021
- Fundamental
- Price
- RLTY $15.61
- SOPH $3.61
- Analyst Decision
- RLTY
- SOPH
- Analyst Count
- RLTY 0
- SOPH 0
- Target Price
- RLTY N/A
- SOPH N/A
- AVG Volume (30 Days)
- RLTY 86.7K
- SOPH 92.4K
- Earning Date
- RLTY 01-01-0001
- SOPH 08-05-2025
- Dividend Yield
- RLTY 9.35%
- SOPH N/A
- EPS Growth
- RLTY N/A
- SOPH N/A
- EPS
- RLTY N/A
- SOPH N/A
- Revenue
- RLTY N/A
- SOPH $69,688,000.00
- Revenue This Year
- RLTY N/A
- SOPH $16.13
- Revenue Next Year
- RLTY N/A
- SOPH $23.80
- P/E Ratio
- RLTY N/A
- SOPH N/A
- Revenue Growth
- RLTY N/A
- SOPH 7.32
- 52 Week Low
- RLTY $11.38
- SOPH $2.58
- 52 Week High
- RLTY $14.60
- SOPH $4.92
- Technical
- Relative Strength Index (RSI)
- RLTY 60.17
- SOPH 59.08
- Support Level
- RLTY $15.26
- SOPH $3.34
- Resistance Level
- RLTY $15.40
- SOPH $3.70
- Average True Range (ATR)
- RLTY 0.16
- SOPH 0.24
- MACD
- RLTY 0.01
- SOPH 0.04
- Stochastic Oscillator
- RLTY 100.00
- SOPH 88.58
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.